目次

Table of Contents

Chapter 1 Methodology and Scope
1.1 Market Segmentation & Scope
1.1.1 Estimates And Forecast Timeline
1.2 Research Methodology
1.3 Information Procurement
1.3.1 Purchased Database
1.3.2 GVR’s Internal Database
1.3.3 Secondary Sources
1.3.4 Primary Research
1.3.5 Details of Primary Research
1.4 Information or Data Analysis
1.4.1 Data Analysis Models
1.5 Market Formulation & Validation
1.6 Region Wise Market Calculation
1.6.1 Region Wise Market: Base Estimates
1.6.2 Global Market: CAGR Calculation
1.7 List of Secondary Sources
1.8 Objectives
1.8.1 Objective - 1: Understanding market dynamics
1.8.2 Objective - 2: Understanding market estimates and forecasts
1.8.3 Objective - 3: Understanding attributes such as strategy framework and competitor categorization
1.8.4 Objective - 4: Understanding the key service and application scopes to conclude on the market size.

Chapter 2 Executive Summary
2.1 Market Outlook

Chapter 3 Global Investigational New Drug CDMO Market: Variables, Trends, & Scope
3.1 Market Segmentation and Scope
3.2 Market Dynamics
3.2.1 Market Driver Analysis
3.2.1.1 Increasing outsourcing services by pharmaceutical companies
3.2.1.2 Rising investment in R&D
3.2.1.3 Growing pharmaceutical industry
3.2.1.5 Stringent regulatory requirements
3.2.2 Market Restraint Analysis
3.2.2.1 Compliance issues while outsourcing
3.2.2.2 Changing scenario in developing countries
3.3 Penetration & Growth Prospect Mapping
3.4 COVID-19 Impact on the Market
3.5 Major Deals and Strategic Alliances Analysis
3.6 Global Investigational New Drug CDMO: Market Analysis Tools
3.6.1 Industry Analysis - Porter’s
3.6.3 PESTEL Analysis

Chapter 4 Global Investigational New Drug CDMO Market: Product Segment Analysis
4.1 Global Investigational New Drug CDMO Market: Product Market Share Analysis, 2023 & 2030
4.2 Small Molecule
4.2.1 Small Molecule Market, 2018 - 2030 (USD Million)
4.3 Large Molecule
4.3.1 Large Molecule Market, 2018 - 2030 (USD Million)

Chapter 5 Global Investigational New Drug CDMO Market: Service Segment Analysis
5.1 Global Investigational New Drug CDMO Market: Service Market Share Analysis, 2023 & 2030
5.2 Contract Development
5.2.1 Contract Development market, 2018 - 2030 (USD Million)
5.2.2 Small Molecule
5.2.2.1 Small Molecule market, 2018 - 2030 (USD Million)
5.2.2.2.1 Bioanalysis and DMPK studies
5.2.2.2.2 Bioanalysis and DMPK studies market, 2018 - 2030 (USD Million)
5.2.2.2.3 Toxicology Testing
5.2.2.2.4 Toxicology Testing market, 2018 - 2030 (USD Million)
5.2.2.2.5 Pathology and safety pharmacology studies
5.2.2.2.6 Pathology and safety pharmacology studies market, 2018 - 2030 (USD Million)
5.2.2.2.7 Drug substance synthetic route development
5.2.2.2.8 Drug substance synthetic route development market, 2018 - 2030 (USD Million)
5.2.2.2.9 Drug substance process development
5.2.2.2.10 Drug substance process development market, 2018 - 2030 (USD Million)
5.2.2.2.11 Drug substance synthetic route development
5.2.2.2.12 Drug substance synthetic route development market, 2018 - 2030 (USD Million)
5.2.2.2.13 Form selection crystallization process development
5.2.2.2.14 Form selection crystallization process development market, 2018 - 2030 (USD Million)
5.2.2.2.15 Scale up of drug substance
5.2.2.2.16 Scale up of drug substance market, 2018 - 2030 (USD Million)
5.2.2.2.17 Preformulation
5.2.2.2.18 Preformulation market, 2018 - 2030 (USD Million)
5.2.2.2.19 Preclinical formulation selection
5.2.2.2.20 Preclinical formulation selection market, 2018 - 2030 (USD Million)
5.2.2.2.21 First in Man Formulation/ Process Development
5.2.2.2.22 First in Man Formulation/ Process Development market, 2018 - 2030 (USD Million)
5.2.2.2.23 Analytical method development / validation
5.2.2.2.24 Analytical method development / validation market, 2018 - 2030 (USD Million)
5.2.2.2.25 Release testing of drug substance and drug product
5.2.2.2.25 Release testing of drug substance and drug product market, 2018 - 2030 (USD Million)
5.2.2.2.26 Work up Purification Steps
5.2.2.2.27 Work up purification steps market, 2018 - 2030 (USD Million)
5.2.2.2.28 Telescoping & Process Refining
5.2.2.2.29 Telescoping & Process Refining market, 2018 - 2030 (USD Million)
5.2.2.2.30 Initial Optimization
5.2.2.2.31 Initial Optimization market, 2018 - 2030 (USD Million)
5.2.2.2.32 Formal stability of drug substance and drug product
5.2.2.2.33 Formal stability of drug substance and drug product market, 2018 - 2030 (USD Million)
5.2.3 Large Molecule
5.2.3.1 Large Molecule market, 2018 - 2030 (USD Million)
5.2.3.2 Cell Line development
5.2.3.3 Cell line development market, 2018 - 2030 (USD Million)
5.2.3.4 Process development
5.2.3.5 Process development market, 2018 - 2030 (USD Million)
5.2.3.4.1 Upstream
5.2.3.4.1.1 Upstream market, 2018 - 2030 (USD Million)
5.2.3.4.1.2 Microbial
5.2.3.4.1.3 Microbial market, 2018 - 2030 (USD Million)
5.2.3.4.1.4 Mammalian
5.2.3.4.1.5 Mammalian market, 2018 - 2030 (USD Million)
5.2.3.4.1.6 Others
5.2.3.4.1.7 Others market, 2018 - 2030 (USD Million)
5.2.3.4.1.8 Upstream
5.2.3.4.1.9 Upstream market, 2018 - 2030 (USD Million)
5.2.3.4.2 Downstream
5.2.3.4.2.1 Downstream market, 2018 - 2030 (USD Million)
5.2.3.4.2.2 MABs
5.2.3.4.2.3 MABs market, 2018 - 2030 (USD Million)
5.2.3.4.2.4 Recombinant Proteins
5.2.3.4.2.5 Recombinant Proteins market, 2018 - 2030 (USD Million)
5.2.3.4.2.6 Others
5.2.3.4.2.7 Others market, 2018 - 2030 (USD Million)
5.3 Contract Manufacturing
5.3.1 Contract Manufacturing market, 2018 - 2030 (USD Million)
5.3.1.1 Small Molecule
5.3.1.2 Small Molecule market, 2018 - 2030 (USD Million)
5.3.1.1.1 Oral Solids
5.3.1.1.2 Oral Solids market, 2018 - 2030 (USD Million)
5.3.1.1.1 Liquid & Semi-solids
5.3.1.1.2 Liquid & Semi-solids market, 2018 - 2030 (USD Million)
5.3.1.1.3 Injectables
5.3.1.1.4 Injectables market, 2018 - 2030 (USD Million)
5.3.1.1.5 Others
5.3.1.1.6 Others market, 2018 - 2030 (USD Million)
5.3.2 Large Molecule
5.3.2.1 Large Molecule market, 2018 - 2030 (USD Million)
5.3.2.1.1 MABs
5.3.2.1.2 MABs market, 2018 - 2030 (USD Million)
5.3.2.1.3 Recombinant Proteins
5.3.2.1.4 Recombinant Proteins market, 2018 - 2030 (USD Million)
5.3.2.1.5 MABs
5.3.2.1.6 MABs market, 2018 - 2030 (USD Million)
5.3.2.1.7 Others
5.3.2.1.8 Others market, 2018 - 2030 (USD Million)

Chapter 6 Global Investigational New Drug CDMO Market: End-user Segment Analysis
6.1 Global Investigational New Drug CDMO Market: End-user Market Share Analysis, 2023 & 2030
6.2 Pharmaceutical Companies
6.2.1 Pharmaceutical companies Investigational New Drug CDMO Market, 2018 - 2030 (USD Million)
6.3 Biotech
6.3.2. Biotech Companies Investigational New Drug CDMO Market, 2018 - 2030 (USD Million)
6.4 Others
6.4.2. Others Investigational New Drug CDMO Market, 2018 - 2030 (USD Million)

Chapter 7 Global Investigational New Drug CDMO Market: Regional Analysis
7.1 Global Investigational New Drug CDMO Market: Regional Market Share Analysis, 2023 & 2030
7.2 North America
7.2.1 North America Investigational New Drug CDMO Market, 2018 - 2030 (USD Million)
7.2.2 U.S.
7.2.2.1 U.S. Investigational New Drug CDMO Market, 2018 - 2030 (USD Million)
7.2.3 Canada
7.2.3.1 Canada Investigational New Drug CDMO Market, 2018 - 2030 (USD Million)
7.3 Europe
7.3.1 Europe Investigational New Drug CDMO Market, 2018 - 2030 (USD Million)
7.3.2 U.K.
7.3.2.1 U.K. Investigational New Drug CDMO Market, 2018 - 2030 (USD Million)
7.3.3 Germany
7.3.3.1 Germany Investigational New Drug CDMO Market, 2018 - 2030 (USD Million)
7.3.4 France
7.3.4.1 France Investigational New Drug CDMO Market, 2018 - 2030 (USD Million)
7.3.5 Italy
7.3.5.1 Italy Investigational New Drug CDMO Market, 2018 - 2030 (USD Million)
7.3.6 Spain
7.3.6.1 Spain Investigational New Drug CDMO Market, 2018 - 2030 (USD Million)
7.4 Asia Pacific
7.4.1 Asia Pacific Investigational New Drug CDMO Market, 2018 - 2030 (USD Million)
7.4.2 Japan
7.4.2.1 Japan Investigational New Drug CDMO Market, 2018 - 2030 (USD Million)
7.4.3 China
7.4.3.1 China Investigational New Drug CDMO Market, 2018 - 2030 (USD Million)
7.4.4 India
7.4.4.1 India Investigational New Drug CDMO Market, 2018 - 2030 (USD Million)
7.4.5 Australia
7.4.5.1 Australia Investigational New Drug CDMO Market, 2018 - 2030 (USD Million)
7.4.6 South Korea
7.4.6.1 South Korea Investigational New Drug CDMO Market, 2018 - 2030 (USD Million)
7.5 Latin America
7.5.1 Latin America Investigational New Drug CDMO Market, 2018 - 2030 (USD Million)
7.5.2 Brazil
7.5.2.1 Brazil Investigational New Drug CDMO Market, 2018 - 2030 (USD Million)
7.5.3 Mexico
7.5.3.1 Mexico Investigational New Drug CDMO Market, 2018 - 2030 (USD Million)
7.5.4 Argentina
7.5.4.1 Argentina Investigational New Drug CDMO Market, 2018 - 2030 (USD Million)
7.6 MEA
7.6.1 MEA Investigational New Drug CDMO Market, 2018 - 2030 (USD Million)
7.6.2 South Africa
7.6.2.1 South Africa Investigational New Drug CDMO Market, 2018 - 2030 (USD Million)
7.6.3 Saudi Arabia
7.6.3.1 Saudi Arabia Investigational New Drug CDMO Market, 2018 - 2030 (USD Million)
7.6.4 UAE
7.6.4.1 UAE Investigational New Drug CDMO Market, 2018 - 2030 (USD Million)

Chapter 8 Company Profiles
8.1 Catalent, Inc.
8.1.1 Company Overview
8.1.2 Service Benchmarking
8.1.3 Financial Performance
8.1.4 Strategic Initiatives
8.2 Lonza
8.2.1 Company Overview
8.2.2 Financial Performance
8.2.3 Service Benchmarking
8.2.5 Strategic Initiatives
8.3 Recipharm AB
8.3.1 Company Overview
8.3.2 Service Benchmarking
8.3.3 Strategic Initiatives
8.4 Siegfried Holding AG
8.4.1 Company Overview
8.4.2 Financial Performance
8.4.3 Service Benchmarking
8.5 Patheon Inc.
8.5.1 Company Overview
8.5.2 Financial Performance
8.5.3 Service Benchmarking
8.6 Covance
8.6.1 Company Overview
8.6.2 Financial Performance
8.6.3 Service Benchmarking
8.7 IQVIA Holdings Inc.
8.7.1 Company Overview
8.7.2 Financial Performance
8.7.3 Service Benchmarking
8.7.4 Strategic Initiatives
8.8 Cambrex Corporation
8.8.1 Company Overview
8.8.2 Financial Performance
8.8.3 Service Benchmarking
8.9 Charles River Laboratories International, Inc.
8.9.1 Company Overview
8.9.2 Financial Performance
8.9.3 Service Benchmarking
8.9.4 Strategic Initiatives
8.10 Syneous Health
8.10.1 Company Overview
8.10.2 Financial Performance
8.10.3 Service Benchmarking
8.10.4 Strategic Initiatives